P47(GAG-CRK) Antibody

What is P47gag-crk and what are its key structural components?

P47gag-crk is an oncogene product containing SH2 and SH3 domains that are conserved in several proteins involved in signal transduction, particularly nonreceptor tyrosine kinases. Despite not possessing intrinsic kinase activity, P47gag-crk elevates phosphotyrosine levels in transformed cells through its interaction capabilities. The protein consists almost entirely of these SH2 and SH3 domains, which are indispensable for its transforming activity. These domains function to regulate protein interactions in a phosphotyrosine-dependent manner, enabling P47gag-crk to participate in key cellular signaling pathways .

How does P47gag-crk function in cellular transformation?

P47gag-crk mediates cellular transformation without directly phosphorylating proteins at tyrosine residues. Instead, it elevates phosphotyrosine content in transformed cells by binding to a broad range of phosphotyrosine-containing proteins. This binding occurs through its SH2 domain, which specifically recognizes phosphotyrosine motifs. Studies demonstrate that P47gag-crk can bind phosphotyrosine-containing proteins from both crk-transformed cells and cells transformed by oncogenic tyrosine kinases such as v-src and v-yes. This interaction capability is central to its transformation mechanism, as it allows P47gag-crk to modulate signaling pathways by functioning as an adaptor protein that recruits and organizes signaling complexes .

What expression systems are effective for producing recombinant P47gag-crk for antibody generation?

The baculovirus expression system has proven highly effective for producing recombinant P47gag-crk in significant quantities. Research demonstrates that approximately 2-10 mg of P47gag-crk can be produced from 10^9 insect cells infected with a recombinant baculovirus. This expression system yields functional P47gag-crk protein that maintains its characteristic properties, including association with tyrosine kinases and their substrates. Purification can be achieved through various approaches, with immunoaffinity chromatography providing the highest purity (resulting in a single band by Coomassie Blue staining). The functionality of insect cell-expressed P47gag-crk makes this system particularly valuable for generating material for antibody production and further biochemical analyses .

How can researchers verify the specificity of P47gag-crk antibodies for immunoprecipitation studies?

Verification of P47gag-crk antibody specificity for immunoprecipitation requires multiple control experiments. Researchers should:

• Perform parallel immunoprecipitations with both the specific antibody and control IgG from the same species

• Include competition assays with recombinant P47gag-crk protein to demonstrate signal reduction

• Validate results using multiple antibodies targeting different epitopes of P47gag-crk

• Compare phosphotyrosine patterns in immunoprecipitates with anti-P47gag-crk versus anti-phosphotyrosine antibodies

In experimental validation, the association between P47gag-crk and its binding partners can be confirmed when the same cellular phosphoproteins coimmunoprecipitate with both anti-P47gag-crk antibodies and anti-phosphotyrosine antibodies. V8 protease mapping can further validate the identity of these interacting proteins . Additionally, sequential immunoprecipitation experiments where lysates are first treated with anti-phosphotyrosine antibodies followed by anti-P47gag-crk can determine whether the interactions are phosphotyrosine-dependent .

What experimental approaches best demonstrate P47gag-crk's interaction with phosphotyrosine-containing proteins?

To effectively demonstrate P47gag-crk's interactions with phosphotyrosine-containing proteins, researchers should employ a multi-faceted approach:

• Coimmunoprecipitation assays using anti-P47gag-crk antibodies followed by immunoblotting with anti-phosphotyrosine antibodies

• Reciprocal coimmunoprecipitation with anti-phosphotyrosine antibodies followed by P47gag-crk detection

• In vitro binding assays using purified recombinant P47gag-crk and phosphotyrosine-containing proteins

• Sequential immunoprecipitation experiments to deplete phosphotyrosine proteins and demonstrate binding specificity

Evidence from published work shows that P47gag-crk can effectively bind to phosphotyrosine-containing proteins of 135, 120, 94, 87, and 65-75 kD from lysates of crk-transformed cells. Binding specificity can be demonstrated by showing that dephosphorylation of target proteins (such as p60v-src) abolishes their association with P47gag-crk, confirming the phosphotyrosine-dependency of these interactions .

What are the recommended methods for evaluating P47gag-crk phosphorylation status?

To comprehensively evaluate P47gag-crk phosphorylation status, researchers should implement:

• Phosphotyrosine-specific immunoblotting following P47gag-crk immunoprecipitation

• Phospho-amino acid analysis to distinguish between phosphotyrosine, phosphoserine, and phosphothreonine modifications

• Peptide mapping of P47gag-crk expressed in different cell types to identify conserved phosphorylation sites

• Mass spectrometry analysis for precise identification of phosphorylation sites

Research demonstrates that P47gag-crk expressed in insect, rat, and chicken cells exhibits similar phosphorylation patterns, suggesting conservation of these modifications across expression systems. Peptide mapping has successfully shown that similar sites are phosphorylated in P47gag-crk regardless of the cellular context, supporting the functional relevance of these modifications . For the most detailed phosphorylation analysis, mass spectrometry approaches provide site-specific information that can be correlated with functional outcomes.

What are the optimal fixation and staining protocols for detecting P47gag-crk in tissue sections?

For effective detection of P47gag-crk in tissue sections, researchers should consider:

• Fixation: 4% paraformaldehyde provides good antigen preservation while maintaining cellular architecture

• Antigen retrieval: Citrate buffer (pH 6.0) heat-mediated retrieval improves antibody access to epitopes

• Blocking: 5-10% normal serum from the species of secondary antibody origin plus 0.1-0.3% Triton X-100

• Primary antibody incubation: Overnight at 4°C using optimized concentration (typically 1-5 μg/mL)

• Detection: Fluorescent secondary antibodies (such as Alexa Fluor 350-conjugated secondary) enable high-sensitivity detection and multi-parameter imaging

For paraffin-embedded sections specifically, anti-P47 antibodies conjugated with fluorophores like Alexa Fluor 350 have been successfully employed for immunofluorescence applications. Working concentration of approximately 1 μg/μL has been reported as effective for tissue section analysis . Appropriate controls should include omission of primary antibody and use of competing peptide to confirm staining specificity.

What methods can detect interactions between P47gag-crk and associated proteins in intact cells?

For studying P47gag-crk interactions in intact cells, consider these approaches:

• Proximity ligation assay (PLA): Enables visualization of protein-protein interactions with subcellular resolution

• Fluorescence resonance energy transfer (FRET): Detects direct interactions between fluorescently-tagged P47gag-crk and binding partners

• Bimolecular fluorescence complementation (BiFC): Confirms direct interactions by reconstituting a fluorescent protein when two fragments are brought together by interacting proteins

• Immunofluorescence colocalization: While less definitive, provides initial evidence of potential interactions

These techniques are particularly valuable for validating interactions identified through biochemical methods like coimmunoprecipitation. For instance, FRET analysis between fluorescently-tagged P47gag-crk and phosphotyrosine-containing proteins can demonstrate direct interactions while preserving cellular architecture and compartmentalization. When selecting an approach, researchers should consider the spatial resolution required, whether direct or indirect interactions are being studied, and whether quantitative measurements are needed .

How can researchers isolate high-purity P47gag-crk for antibody generation and validation?

To isolate high-purity P47gag-crk suitable for antibody production, consider this methodological approach:

• Expression system selection: Baculovirus expression in insect cells yields 2-10 mg of P47gag-crk per 10^9 cells

• Initial purification: Precipitation in low salt buffer followed by gel filtration

• Advanced purification: Immunoaffinity chromatography using existing antibodies against P47gag-crk

• Purity assessment: SDS-PAGE with Coomassie Blue staining to confirm single-band purity

• Functional validation: Verify that purified P47gag-crk retains ability to associate with tyrosine kinases and substrates

Research demonstrates that immunoaffinity chromatography provides the highest purity of P47gag-crk, yielding a preparation that appears as a single band by Coomassie Blue staining. Importantly, P47gag-crk purified from insect cells maintains its functional characteristics, associating in vitro with tyrosine kinases and their substrates from Crk-3Y1 cells, making it suitable for both antibody production and functional studies .

How can researchers distinguish between specific and non-specific binding in P47gag-crk coimmunoprecipitation experiments?

To differentiate specific from non-specific binding in P47gag-crk coimmunoprecipitation studies:

• Include appropriate negative controls: IgG from the same species as the primary antibody

• Perform competition experiments: Add excess recombinant P47gag-crk to demonstrate specific signal reduction

• Use multiple antibodies: Employ antibodies against different P47gag-crk epitopes to confirm consistent findings

• Validate with reciprocal immunoprecipitation: Confirm interactions by immunoprecipitating the binding partner and detecting P47gag-crk

• Sequential immunoprecipitation: Pre-clear lysates with anti-phosphotyrosine antibodies before P47gag-crk immunoprecipitation

Published results demonstrate that cellular phosphoproteins that coimmunoprecipitate with P47gag-crk using anti-Gag or anti-Crk antibodies are identical to those precipitated with anti-phosphotyrosine antibodies, as validated by V8 protease mapping. This approach provides strong evidence for specific interactions. Additionally, specificity can be confirmed by showing that pre-treating cell lysates with anti-phosphotyrosine antibodies prevents subsequent immunoprecipitation of phosphoproteins with anti-P47gag-crk antibodies .

What experimental controls are essential when studying P47gag-crk-mediated cellular transformation?

When investigating P47gag-crk-mediated cellular transformation, implement these critical controls:

• Vector-only controls: Cells transfected with empty vector to establish baseline transformation metrics

• Catalytically inactive mutants: Cells expressing P47gag-crk with mutations in key functional domains (SH2 or SH3)

• Phosphotyrosine levels: Monitor phosphotyrosine content as a marker of transformation across experimental conditions

• Transformation markers: Assess multiple independent markers (focus formation, anchorage-independent growth, morphological changes)

• Cell-type specificity: Compare transformation efficiency across multiple cell types to determine context-dependence

Research has established that P47gag-crk expression increases cellular phosphotyrosine content, a characteristic feature of crk-transformed cells. This provides a quantifiable marker for transformation that should be measured alongside morphological and growth characteristics. Additionally, structure-function studies using domain-specific mutants can pinpoint which regions of P47gag-crk are essential for each aspect of cellular transformation .

What are the key considerations for selecting between polyclonal and monoclonal P47gag-crk antibodies?

When choosing between polyclonal and monoclonal P47gag-crk antibodies, consider:

For P47gag-crk research, polyclonal antibodies are particularly valuable for initial characterization and protein complex identification, as they can recognize multiple epitopes and maintain reactivity even if some phosphorylation events alter certain epitopes. Conversely, monoclonal antibodies provide the consistency needed for quantitative studies and applications requiring maximal specificity, such as distinguishing between closely related protein family members .

How can P47gag-crk antibodies be utilized to study SH2/SH3 domain interactions in normal and pathological signaling?

P47gag-crk antibodies offer valuable tools for investigating SH2/SH3 domain interactions through:

• Immunoprecipitation followed by mass spectrometry to identify the complete interactome of P47gag-crk in various cellular contexts

• ChIP-seq applications to identify potential roles of P47gag-crk in transcriptional regulation

• Proximity-based labeling methods (BioID, APEX) coupled with P47gag-crk antibodies for validation

• Super-resolution microscopy to visualize the spatial organization of P47gag-crk-containing signaling complexes

Research has established that P47gag-crk binds to a broad range of phosphotyrosine-containing proteins through its SH2 domain, while its SH3 domain likely mediates other protein interactions. These domains are conserved across many signaling proteins, making P47gag-crk an excellent model for studying domain-specific interactions. By immunoprecipitating P47gag-crk and identifying its binding partners under various conditions (e.g., growth factor stimulation, cellular stress), researchers can map the dynamic interactome of SH2/SH3 domains and their roles in normal and pathological signaling pathways .

What are the current challenges in developing phospho-specific antibodies for P47gag-crk research?

Developing phospho-specific P47gag-crk antibodies presents several technical challenges:

• Identifying the physiologically relevant phosphorylation sites on P47gag-crk

• Generating antibodies with high specificity for individual phosphorylation sites

• Validating antibody specificity across multiple experimental systems

• Ensuring consistent performance across applications (Western blot, immunoprecipitation, immunofluorescence)

How can P47gag-crk antibodies contribute to understanding oncogenic transformation mechanisms?

P47gag-crk antibodies can advance our understanding of oncogenic transformation through:

• Comparative analysis of P47gag-crk-interacting proteins across normal, pre-malignant, and malignant cells

• Tracking P47gag-crk localization during different stages of cellular transformation

• Studying how P47gag-crk complexes change during acquisition of drug resistance

• Evaluating P47gag-crk as a potential biomarker for transformation status

Since P47gag-crk binds to a wide range of phosphotyrosine-containing proteins in transformed cells, antibodies against this protein provide powerful tools for studying the phosphotyrosine-dependent protein interactions that drive oncogenic transformation. Research has established that P47gag-crk binds to phosphotyrosine-containing proteins from both crk-transformed cells and cells transformed by various oncogenic tyrosine kinases, suggesting common mechanisms across transformation pathways . By using anti-P47gag-crk antibodies to isolate and characterize these protein complexes, researchers can identify novel therapeutic targets and better understand the signaling networks that support malignant transformation.